

The Manager  
 Company Announcements Office  
 ASX Limited

## INFORMATION REQUIRED UNDER ASX LISTING RULE 3.10.5A

**Adelaide, 11 June 2019:** LBT Innovations Ltd provides the following information required under ASX Listing Rule 3.10.5A.

a) Dilution to existing holders:

The dilutive effect of the 7.1A placement of 20,092,702 fully paid ordinary shares on existing shareholders is 9.1%.

Further details of the approximate percentage of the issued capital post the placement held by pre-placement shareholders and the new shareholders are as follows;

<i>Shareholder category</i>	<i>Holding pre placement</i>	<i>Holding post placement</i>
Pre-placement security holders who did not participate in the placement	96.8%	89.2%
Pre-placement security holders who did participate in the placement	3.2%	3.9%
Participants in the placement who were not previously security holders	-	6.9%
Total	100%	100%

- b) The Company has resolved to utilise the capacity available to it under ASX Listing Rule 7.1A. The Company considers this to be the most effective and expedient method for raising funds to accelerate sales activities, ongoing software development and general working capital;
- c) No underwriting arrangement were in place for the placement; and
- d) \$174,806 in fees were paid in connection with the placement.

– ENDS –

### About LBT Innovations

LBT Innovations (LBT) improves patient outcomes by making healthcare more efficient. Based in Adelaide, South Australia, the Company has a history of developing world leading products in microbiology automation. Its first product, MicroStreak®, was a global first in the automation of the culture plate streaking process. The Company's second product, the Automated Plate Assessment System (APAS®) is being commercialised through LBT's 50% owned joint venture company Clever Culture Systems AG (CCS) with Hettich Holding Beteiligungs- und Verwaltungs-GmbH. The APAS® instrument is based upon LBT's intelligent imaging and machine learning software and remains the only US FDA-cleared artificial intelligence technology for automated imaging, analysis and interpretation of culture plates following incubation.

### CONTACTS

<b>LBT Innovations</b>	<b>Investor Enquiries</b>
<b>Brent Barnes</b> Chief Executive Officer & Managing Director Tel: +61 8 8227 1555 E: <a href="mailto:info@lbtinnovations.com">info@lbtinnovations.com</a>	<b>David Allen / John Granger</b> Hawkesbury Partners Tel: +61 2 9103 9494 E: <a href="mailto:dallen@hawkesburypartners.com">dallen@hawkesburypartners.com</a>